The Chennai glaucoma survey results – Available in Indian Journal of ophthalmology - Year : 2010 | Volume : 58 | Issue : 3 | Page : 243-245

Report generated after 3850 subjects participated in the study. Most important outcome of the study is, 15 aphakes and 23 pseudophakes (total 38) (0.99% of 3850 subjects) of the 406 persons who had undergone cataract surgery were diagnosed with glaucoma. It is understoond that risk of glaucoma is higher in Aphakes/pseudophakes as compared to the phakic population (Odds Ratio: 2.71, 95% CI: 1. 94, 3.38, p=0.001). 20% of aphakic and 4.3% of pseudophakic eyes detected with Blindness attributable to glaucoma.

More details found in the below link:

http://www.ijo.in/article.asp?issn=0301-4738;year=2010;volume=58;issue=3;spage=243;epage=245;aulast=George

Hope this information is useful and enjoy reading all the contents of the article…

With best wishes,

Dr. Shiva Murthy N
Director-Clinical Research and Business Development,
Quartesian CRO

Introduction on ‘Journal of Pharmacy and BioAllied Sciences' (JPBS)

I am pleased to introduce 'Journal of Pharmacy and BioAllied Sciences' (JPBS). This journal was launched from the year 2009. The policy of the journal is to publish innovative articles, reviews, mini-reviews, rapid communications, and notes, dealing with all branches of Pharmaceutical Sciences, Medicinal / Analytical Chemistry, Biotechnology, and Bioallied Sciences, related to the conception, design, production, characterization, and evaluation of drugs and their delivery systems in vitro and in vivo. The journal is interested to publish articles on: Pharmaceutics, Pharmacy Practice, Drug Regulatory Affairs, Pharmacology, Synthesis of Novel Medicinal Compounds, Analytical Sciences, Phytomedicine, Nanotechnology, Physical Pharmacy, Polymer Chemistry, and Microbiology, as applied to pharmaceutical, medical, and health sciences. The official website the journal is www.jpbsonline.org, and online submission of manuscripts can also be done at www.journalonweb.com/jpbs.

Hope this information is useful and enjoy reading all the issues…

With best wishes,

Dr. Shiva Murthy N

PLGA is a suitable biomaterial or polymer for the preparation of novel drug delivery

I found this article as an interesting one. I hope many readers are interested in this. The article conveys following important messages:


1. Poly (D, L-lactide-co-glycolide) (PLGA) is approved by the Food and Drug Administration for drug delivery use.
2. The polymeric nanoparticles based on PLGA and its co-polymer are designed for controlled and targeted drug delivery. Also, PLGA and its co-polymer are important in designing nanoparticles with desired characteristics such as biocompatibility, biodegradation, particle size, surface properties, drug release and targetability.
3. PLGA-based polymeric nanoparticles loaded with different drugs like Triclosan, Paclitaxel, Ellagic acid, Streptomycin, Estradiol, Cyclosporine, Gentamicin, Risperidone, Adriamycin, Alendronate, Cisplatin, showed effectiveness in their respective therapies.
4. The stealth nanoparticles based on the PLGA co-polymer are developed to overcome the opsonization process during i.v. administration for an improved and targeted drug delivery.

If you want to know more, please download and read from below link

http://www.asiapharmaceutics.info/downloadpdf.asp?issn=0973-8398;year=2009;volume=3;issue=4;spage=266;epage=273;aulast=Muthu;type=2

Quartesian is very happy to bring more information like this.

If you want to know more about Quartesian CRO please visit www.quartesian.com

If you want any of our services, please feel free to contact me.

With best wishes,

Dr. Shiva Murthy N

Director – Clinical Research and Business development
Quartesian CR Pvt Ltd
Shiva.murthy@quartesian.com
shivuindia@yahoo.com
00919345277771
00919677632414

Seizure and Coma due to hyponatremia induced by Vincristine

Patient with stage 1 Wilms tumour, on Vincristine had hyponatremia, presented as generalized tonic clonic seizures and coma. Investigations suggested no localizing neurological signs located to differentiate other causes of seizure. Treatment- Patient intubated and mechanically ventilated. Patient treated with fluid restriction, hypertonic saline (3%) and other supportive care. Patient improved clinically over three days and extubated on the third day and shifted to the ward on the fifth day. Complete report is available in Indian J of Crical Care Medicie, Year : 2009 | Volume : 13 | Issue : 3 | Page : 167—168. Hope it is interesting for you and read more on this. Click below link to view complete report.
http://www.ijccm.org/downloadpdf.asp?issn=0972-5229;year=2009;volume=13;issue=3;spage=167;epage=168;aulast=Nagappa;type=2

Dr. Shivamurthy Nanjundappa, MD (Pharmacology)
Director - Clinical Research and Business Development
Quartesian Clinical Research Pvt Ltd
Official Email ID: shiva.murthy@quartesian.com
Mobile No: +919677632414
Fax: +91-80-41689771
Alternate Email ID: shivuindia@yahoo.com

Rituximab a chimeric monoclonal antibody targets the CD20

Rituximab a chimeric monoclonal antibody targets the CD20 molecule, leading to depletion of B-lymphocytes through antibody-dependent and complement-mediated cytotoxicity as well as by promotion of apoptotic mechanisms. Rituximab has been used in non-Hodgkin type B-cell lymphoma for over a decade,but is now being studied in a number of autoimmune conditions.

It is proposed to be useful for Multiple sclerosis also.

Tamsulosin and alfuzosin are comparable in acute urinary retention

Comparison of alfuzosin and tamsulosin in patients suffering from acute urinary retention caused by benign prostatic hyperplasia (BPH) showed that Both groups had similar results which were significantly superior than placebo. Three months, followup suggested that alfuzosin- or tamsulosin-treated patients showed a significant decrease in AUA score and PVRV; and a significant increase in PFR as compared to placebo. Tamsulosin is considred to have comparable therapeutic benifits as that of alfuzosin in all respects, except a small but significant side effect of retrograde ejaculation. Detailed report available in Indian Journal of Urology (Indian J Urol)
2009 | October-December | Volume 25 | Issue 4.

Dr. Shivamurthy Nanjundappa, MD (Pharmacology)
Director - Clinical Research and Business Development
Quartesian Clinical Research Pvt Ltd
Official Email ID: shiva.murthy@quartesian.com
Mobile No: +919677632414
Fax: +91-80-41689771
Alternate Email ID: shivuindia@yahoo.com

Thank you for your valuable support and being in touch with me. "Happy thanks giving day for all"